Antibody-mediated immunotherapy against chronic hepatitis B virus infection

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Human Vaccines & Immunotherapeutics

• Publication date

  2017-05-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/21645515.2017.1319021PMID 28521640PMCID PMC5557221
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

  2017cited by this paper
• Anti‐retroviral antibody FcγR‐mediated effector functions

  2017cited by this paper
• A novel toolbox for the in vitro assay of hepatitis D virus infection

  2017cited by this paper
• New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus.

  2016cited by this paper
• Aiming for cure in HBV and HDV infection.

  2016cited by this paper
• Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption.

  2016cited by this paper
• Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

  2015cited by this paper
• Rapid fluorescent lateral-flow immunoassay for hepatitis B virus genotyping.

  2015cited by this paper
• Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013.

  2015influential reference
• HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B

  2015cited by this paper
• A unique monoclonal antibody for therapeutic use against chronic hepatitis B: not all antibodies are created equal

  2015cited by this paper
• Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen

  2015cited by this paper
• Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA

  2014cited by this paper
• Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity.

  2014cited by this paper
• Immune Therapeutic Strategies in Chronic Hepatitis B Virus Infection: Virus or Inflammation Control?

  2013cited by this paper
• Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia

  2013cited by this paper
• Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys

  2013cited by this paper
• Effects of Microparticle Size and Fc Density on Macrophage Phagocytosis

  2013cited by this paper
• A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus A‐determinant

  2013cited by this paper
• Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B.

  2012cited by this paper
• Persistent Hepatitis B Viral Replication in a FVB/N Mouse Model: Impact of Host and Viral Factors

  2012cited by this paper
• Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors.

  2012influential reference
• Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.

  2012cited by this paper
• The cell biology of phagocytosis.

  2012cited by this paper
• Identification of Disubstituted Sulfonamide Compounds as Specific Inhibitors of Hepatitis B Virus Covalently Closed Circular DNA Formation

  2012cited by this paper
• Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus

  2012cited by this paper
• Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B

  2011cited by this paper
• Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response

  2011cited by this paper
• Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

  2011cited by this paper
• A novel immunoassay for PreS1 and/or core-related antigens for detection of HBsAg variants.

  2010cited by this paper
• Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B

  2010cited by this paper
• Pathogenesis of hepatitis B virus infection.

  2010cited by this paper
• Analysis of the epitope and neutralizing capacity of human monoclonal antibodies induced by hepatitis B vaccine.

  2010cited by this paper
• Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside‐naïve HBeAg‐positive patients with chronic hepatitis B *

  2010cited by this paper
• Fine Mapping of Pre-S Sequence Requirements for Hepatitis B Virus Large Envelope Protein-Mediated Receptor Interaction

  2009cited by this paper
• Fc receptor-mediated antiviral antibodies

  2009cited by this paper
• A Function Essential to Viral Entry Underlies the Hepatitis B Virus “a” Determinant

  2009cited by this paper
• Hepatitis B virus infection.

  2009cited by this paper
• Identification of androgen response elements in the enhancer I of hepatitis B virus: A mechanism for sex disparity in chronic hepatitis B

  2009cited by this paper
• Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.

  2008cited by this paper
• Pathogenesis of hepatitis B virus infection.

  2007cited by this paper
• Robust expansion of human hepatocytes in Fah−/−/Rag2−/−/Il2rg−/− mice

  2007cited by this paper
• The growth and potential of human antiviral monoclonal antibody therapeutics

  2007cited by this paper
• HBsAg seroclearance in asymptomatic carriers of high endemic areas: Appreciably high rates during a long‐term follow‐up

  2007cited by this paper
• Role of target geometry in phagocytosis.

  2006cited by this paper
• Discontinuous epitopes of hepatitis B surface antigen derived from a filamentous phage peptide library

  2005cited by this paper
• A 'first loop' linear epitope accessible on native hepatitis B surface antigen that persists in the face of 'second loop' immune escape.

  2003cited by this paper
• Escaping High Viral Load Exhaustion: CD8 Cells with Altered Tetramer Binding in Chronic Hepatitis B Virus Infection

  2002cited by this paper
• Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: Safety and antiviral properties

  2002cited by this paper
• Escaping High Viral Load Exhaustion

  2002cited by this paper
• Novel cell permeable motif derived from the PreS2-domain of hepatitis-B virus surface antigens

  2000cited by this paper
• Preclinical Evaluation of Two Human Anti–Hepatitis B Virus (HBV) Monoclonal Antibodies in the HBV‐Trimera Mouse Model and in HBV Chronic Carrier Chimpanzees

  2000cited by this paper
• Characterization of the reactivity pattern of murine monoclonal antibodies against wild‐type hepatitis B surface antigen to g145r and other naturally occurring “a” loop escape mutations

  1999cited by this paper
• Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product.

  1999cited by this paper
• Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group.

  1997cited by this paper
• Discontinuous epitopes of hepatitis B surface antigen derived from a filamentous phage peptide library.

  1996cited by this paper
• Site‐directed mutagenesis of human protein disulphide isomerase: effect on the assembly, activity and endoplasmic reticulum retention of human prolyl 4‐hydroxylase in Spodoptera frugiperda insect cells.

  1992cited by this paper
• Large surface proteins of hepatitis B virus containing the pre-s sequence

  1984cited by this paper
• Two distinct types of hepatitis in experimental hepatitis B virus infection.

  1980cited by this paper

• Chemoenzymatic Synthesis of Nanobody-Peptide Conjugates Capable of Harnessing HBV Vaccine-Induced Antibodies for Cancer Immunotherapy.

  2026cites this paper
• Human hepatitis B immunoglobulins: Standardisation issues

  2025cites this paper
• Engineered Nanobody Chimeras Recruits Anti-HBV Antibodies for Target Cancer Immunotherapy.

  2025cites this paper
• Repurposing vaccine-induced anti-HBV antibodies for endogenous immunotherapy against EGFR-positive tumors.

  2025cites this paper
• mRNA Therapeutic Vaccine for Hepatitis B Demonstrates Immunogenicity and Efficacy in the AAV-HBV Mouse Model

  2024cites this paper
• Circulating HBsAg-specific B cells are partially rescued in chronically HBV-infected patients with functional cure

  2024cites this paper
• CARs derived from broadly neutralizing, human monoclonal antibodies identified by single B cell sorting target hepatitis B virus-positive cells

  2024cites this paper
• Immunoglobulin A and complement C4 are involved in the progression of liver fibrosis in patients with chronic hepatitis B.

  2023cites this paper
• Evaluation of reverse transcription-polymerase chain reaction and simultaneous amplification and testing for quantitative detection of serum hepatitis B virus RNA

  2023cites this paper
• Tenofovir alters the immune microenvironment of pregnant women with hepatitis B virus infection: Evidence from single-cell RNA sequencing.

  2023cites this paper
• Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure

  2023cites this paper
• The Multiple Facets and Disorders of B Cell Functions in Hepatitis B Virus Infection

  2023cites this paper
• Anti-HBc IgG Responses Occurring at the Early Phase of Infection Correlate Negatively with HBV Replication in a Mouse Model

  2022cites this paper
• Hepatitis B functional cure and immune response

  2022cites this paper
• Innate and adaptive immune escape mechanisms of hepatitis B virus

  2022cites this paper
• An age-structured model of hepatitis B viral infection highlights the potential of different therapeutic strategies

  2021cites this paper
• Treatments for HBV: A Glimpse into the Future

  2021cites this paper
• Identification of Therapeutic Targets for the Selective Killing of HBV-Positive Hepatocytes

  2021cites this paper
• B cells were related to HBsAg seroconversion in inactive HBsAg carriers following peginterferon therapy

  2020cites this paper
• Reassessing therapeutic antibodies for neglected and tropical diseases

  2020cites this paper
• Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection

  2020cites this paper
• A new approach for therapeutic vaccination against chronic HBV infections.

  2020cites this paper
• Structure guided maturation of a novel humanized anti-HBV antibody and its preclinical development.

  2020cites this paper
• Public broadly neutralizing antibodies against hepatitis B virus in individuals with elite serologic activity

  2020cites this paper
• A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations.

  2020cites this paper
• Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers

  2020cites this paper
• Aerobic glycolysis supports hepatitis B virus protein synthesis through interaction between viral surface antigen and pyruvate kinase isoform M2

  2020cites this paper
• A dendritic cell receptor-targeted chimeric immunotherapeutic protein (C-HBV) for the treatment of chronic hepatitis B

  2019cites this paper
• Robust in vitro assay for analyzing the neutralization activity of serum specimens against hepatitis B virus

  2019cites this paper
• Toward a Functional Cure for Hepatitis B: The Rationale and Challenges for Therapeutic Targeting of the B Cell Immune Response

  2019cites this paper
• عفونت هپاتیت B: مقاله مروری

  2018cites this paper
• A “sandwich” strategy for functional cure of chronic hepatitis B

  2018cites this paper
• Circulating and intrahepatic antiviral B cells are defective in hepatitis B

  2018cites this paper
• Hepatitis B infection: review article

  2018cites this paper
• An OX40/OX40L interaction directs successful immunity to hepatitis B virus

  2018cites this paper
• Viral envelope-specific antibodies in chronic hepatitis B virus infection.

  2018cites this paper
• Current advances in the elimination of hepatitis B in China by 2030

  2017cites this paper
• Humoral immunity, the underestimated player in hepatitis B

  2017cites this paper
• چالش های باروری و ملاحظات مرتبط با فناوری کمک باروری در زوجین مبتلا به هپاتیت B: (مقاله مروری)

  2016cites this paper
• World Journal of Hepatology

  year unknowncites this paper